Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Antitumor effect of insulin-like growth factor-1 receptor inhibition in head and neck squamous cell carcinoma.

Lehman CE, Khalil AA, Axelrod MJ, Dougherty MI, Schoeff SS, Taniguchi LE, Mendez RE, David AP, McGarey PO Jr.,, Hubbard MA, Donaldson L, Frierson HF Jr.,, Stelow EB, Bekiranov S, Wulfkuhle JD, Petricoin EF, Gioeli DG, Jameson MJ.

Laryngoscope. 2019 Aug 21. doi: 10.1002/lary.28236. [Epub ahead of print]

PMID:
31433065
2.

Development of a multicellular pancreatic tumor microenvironment system using patient-derived tumor cells.

Gioeli D, Snow CJ, Simmers MB, Hoang SA, Figler RA, Allende JA, Roller DG, Parsons JT, Wulfkuhle JD, Petricoin EF, Bauer TW, Wamhoff BR.

Lab Chip. 2019 Mar 27;19(7):1193-1204. doi: 10.1039/c8lc00755a.

PMID:
30839006
3.

Phosphoprotein-based drug target activation mapping for precision oncology: a view to the future.

Pierobon M, Petricoin EF 3rd, Wulfkuhle JD.

Expert Rev Proteomics. 2018 Nov;15(11):851-853. doi: 10.1080/14789450.2018.1531709. Epub 2018 Oct 12. No abstract available.

PMID:
30301389
4.

Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL.

Olshen A, Wolf D, Jones EF, Newitt D, van ‘t Veer LJ, Yau C, Esserman L, Wulfkuhle JD, Gallagher RI, Singer L, Petricoin EF 3rd, Hylton N, Park CC.

J Med Imaging (Bellingham). 2018 Jan;5(1):011014. doi: 10.1117/1.JMI.5.1.011014. Epub 2017 Dec 23.

5.

Heme Binding Biguanides Target Cytochrome P450-Dependent Cancer Cell Mitochondria.

Guo Z, Sevrioukova IF, Denisov IG, Zhang X, Chiu TL, Thomas DG, Hanse EA, Cuellar RAD, Grinkova YV, Langenfeld VW, Swedien DS, Stamschror JD, Alvarez J, Luna F, Galván A, Bae YK, Wulfkuhle JD, Gallagher RI, Petricoin EF Rd, Norris B, Flory CM, Schumacher RJ, O'Sullivan MG, Cao Q, Chu H, Lipscomb JD, Atkins WM, Gupta K, Kelekar A, Blair IA, Capdevila JH, Falck JR, Sligar SG, Poulos TL, Georg GI, Ambrose E, Potter DA.

Cell Chem Biol. 2017 Oct 19;24(10):1314. doi: 10.1016/j.chembiol.2017.09.012. No abstract available.

6.

Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL.

Jayappa KD, Portell CA, Gordon VL, Capaldo BJ, Bekiranov S, Axelrod MJ, Brett LK, Wulfkuhle JD, Gallagher RI, Petricoin EF, Bender TP, Williams ME, Weber MJ.

Blood Adv. 2017 Jun 13;1(14):933-946. Erratum in: Blood Adv. 2017 Aug 17;1(19):1537.

7.

Heme Binding Biguanides Target Cytochrome P450-Dependent Cancer Cell Mitochondria.

Guo Z, Sevrioukova IF, Denisov IG, Zhang X, Chiu TL, Thomas DG, Hanse EA, Cuellar RAD, Grinkova YV, Langenfeld VW, Swedien DS, Stamschror JD, Alvarez J, Luna F, Galván A, Bae YK, Wulfkuhle JD, Gallagher RI, Petricoin EF Rd, Norris B, Flory CM, Schumacher RJ, O'Sullivan MG, Cao Q, Chu H, Lipscomb JD, Atkins WM, Gupta K, Kelekar A, Blair IA, Capdevila JH, Falck JR, Sligar SG, Poulos TL, Georg GI, Ambrose E, Potter DA.

Cell Chem Biol. 2017 Oct 19;24(10):1259-1275.e6. doi: 10.1016/j.chembiol.2017.08.009. Epub 2017 Sep 14. Erratum in: Cell Chem Biol. 2017 Oct 19;24(10):1314.

8.

Innovations in Clinical Trial Design in the Era of Molecular Profiling.

Wulfkuhle JD, Spira A, Edmiston KH, Petricoin EF 3rd.

Methods Mol Biol. 2017;1606:19-36. doi: 10.1007/978-1-4939-6990-6_2. Review.

PMID:
28501991
9.

A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancer.

Jameson GS, Petricoin EF, Sachdev J, Liotta LA, Loesch DM, Anthony SP, Chadha MK, Wulfkuhle JD, Gallagher RI, Reeder KA, Pierobon M, Fulk MR, Cantafio NA, Dunetz B, Mikrut WD, Von Hoff DD, Robert NJ.

Breast Cancer Res Treat. 2014 Oct;147(3):579-88. doi: 10.1007/s10549-014-3117-1. Epub 2014 Sep 11.

PMID:
25209003
10.

An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.

Xia W, Petricoin EF 3rd, Zhao S, Liu L, Osada T, Cheng Q, Wulfkuhle JD, Gwin WR, Yang X, Gallagher RI, Bacus S, Lyerly HK, Spector NL.

Breast Cancer Res. 2013;15(5):R85.

11.

Systems analysis of the NCI-60 cancer cell lines by alignment of protein pathway activation modules with "-OMIC" data fields and therapeutic response signatures.

Federici G, Gao X, Slawek J, Arodz T, Shitaye A, Wulfkuhle JD, De Maria R, Liotta LA, Petricoin EF 3rd.

Mol Cancer Res. 2013 Jun;11(6):676-85. doi: 10.1158/1541-7786.MCR-12-0690. Epub 2013 May 1.

12.

Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping.

Wulfkuhle JD, Berg D, Wolff C, Langer R, Tran K, Illi J, Espina V, Pierobon M, Deng J, DeMichele A, Walch A, Bronger H, Becker I, Waldhör C, Höfler H, Esserman L; I-SPY 1 TRIAL Investigators, Liotta LA, Becker KF, Petricoin EF 3rd.

Clin Cancer Res. 2012 Dec 1;18(23):6426-35. doi: 10.1158/1078-0432.CCR-12-0452. Epub 2012 Oct 8.

13.

BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib.

Godinho MF, Wulfkuhle JD, Look MP, Sieuwerts AM, Sleijfer S, Foekens JA, Petricoin EF 3rd, Dorssers LC, van Agthoven T.

Br J Cancer. 2012 Sep 4;107(6):947-55. doi: 10.1038/bjc.2012.351. Epub 2012 Aug 14.

14.

Protein pathway activation mapping reveals molecular networks associated with antiestrogen resistance in breast cancer cell lines.

van Agthoven T, Godinho MF, Wulfkuhle JD, Petricoin EF 3rd, Dorssers LC.

Int J Cancer. 2012 Nov 1;131(9):1998-2007. doi: 10.1002/ijc.27489. Epub 2012 Mar 20.

15.

Proteomic analysis of eccrine sweat: implications for the discovery of schizophrenia biomarker proteins.

Raiszadeh MM, Ross MM, Russo PS, Schaepper MA, Zhou W, Deng J, Ng D, Dickson A, Dickson C, Strom M, Osorio C, Soeprono T, Wulfkuhle JD, Petricoin EF, Liotta LA, Kirsch WM.

J Proteome Res. 2012 Apr 6;11(4):2127-39. doi: 10.1021/pr2007957. Epub 2012 Feb 27.

16.

Compensatory pathways induced by MEK inhibition are effective drug targets for combination therapy against castration-resistant prostate cancer.

Gioeli D, Wunderlich W, Sebolt-Leopold J, Bekiranov S, Wulfkuhle JD, Petricoin EF 3rd, Conaway M, Weber MJ.

Mol Cancer Ther. 2011 Sep;10(9):1581-90. doi: 10.1158/1535-7163.MCT-10-1033. Epub 2011 Jun 28.

17.

Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors.

Xia W, Liu Z, Zong R, Liu L, Zhao S, Bacus SS, Mao Y, He J, Wulfkuhle JD, Petricoin EF 3rd, Osada T, Yang XY, Hartman ZC, Clay TM, Blackwell KL, Lyerly HK, Spector NL.

Mol Cancer Ther. 2011 Aug;10(8):1367-74. doi: 10.1158/1535-7163.MCT-10-0991. Epub 2011 Jun 14.

18.

Protein pathway activation mapping of brain metastasis from lung and breast cancers reveals organ type specific drug target activation.

Improta G, Zupa A, Fillmore H, Deng J, Aieta M, Musto P, Liotta LA, Broaddus W, Petricoin EF 3rd, Wulfkuhle JD.

J Proteome Res. 2011 Jul 1;10(7):3089-97. doi: 10.1021/pr200065t. Epub 2011 May 27.

19.

Protein microarray analysis of mammary epithelial cells from obese and nonobese women at high risk for breast cancer: feasibility data.

Pilie PG, Ibarra-Drendall C, Troch MM, Broadwater G, Barry WT, Petricoin EF 3rd, Wulfkuhle JD, Liotta LA, Lem S, Baker JC Jr, Stouder A, Ford AC, Wilke LG, Zalles CM, Mehta P, Williams J, Shivraj M, Su Z, Geradts J, Yu D, Seewaldt VL.

Cancer Epidemiol Biomarkers Prev. 2011 Mar;20(3):476-82. doi: 10.1158/1055-9965.EPI-10-0847. Epub 2011 Jan 17.

20.

Comparison of global versus epidermal growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancer.

Havaleshko DM, Smith SC, Cho H, Cheon S, Owens CR, Lee JK, Liotta LA, Espina V, Wulfkuhle JD, Petricoin EF, Theodorescu D.

Neoplasia. 2009 Nov;11(11):1185-93.

21.

Quantitative cell signalling analysis reveals down-regulation of MAPK pathway activation in colorectal cancer.

Gulmann C, Sheehan KM, Conroy RM, Wulfkuhle JD, Espina V, Mullarkey MJ, Kay EW, Liotta LA, Petricoin EF 3rd.

J Pathol. 2009 Aug;218(4):514-9. doi: 10.1002/path.2561.

PMID:
19396842
22.

Pathway biomarker profiling of localized and metastatic human prostate cancer reveal metastatic and prognostic signatures.

Grubb RL, Deng J, Pinto PA, Mohler JL, Chinnaiyan A, Rubin M, Linehan WM, Liotta LA, Petricoin EF, Wulfkuhle JD.

J Proteome Res. 2009 Jun;8(6):3044-54. doi: 10.1021/pr8009337.

23.

Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy.

Wulfkuhle JD, Speer R, Pierobon M, Laird J, Espina V, Deng J, Mammano E, Yang SX, Swain SM, Nitti D, Esserman LJ, Belluco C, Liotta LA, Petricoin EF 3rd.

J Proteome Res. 2008 Apr;7(4):1508-17. doi: 10.1021/pr7008127. Epub 2008 Feb 8.

PMID:
18257519
24.

Reverse phase protein microarrays for monitoring biological responses.

Espina V, Wulfkuhle JD, Calvert VS, Petricoin EF 3rd, Liotta LA.

Methods Mol Biol. 2007;383:321-36. doi: 10.1007/978-1-59745-335-6_21.

PMID:
18217695
25.

Laser-capture microdissection.

Espina V, Wulfkuhle JD, Calvert VS, VanMeter A, Zhou W, Coukos G, Geho DH, Petricoin EF 3rd, Liotta LA.

Nat Protoc. 2006;1(2):586-603.

PMID:
17406286
26.

Technology insight: pharmacoproteomics for cancer--promises of patient-tailored medicine using protein microarrays.

Wulfkuhle JD, Edmiston KH, Liotta LA, Petricoin EF 3rd.

Nat Clin Pract Oncol. 2006 May;3(5):256-68. Review.

PMID:
16683004
27.

Reverse-phase protein microarrays for tissue-based analysis.

Speer R, Wulfkuhle JD, Liotta LA, Petricoin EF 3rd.

Curr Opin Mol Ther. 2005 Jun;7(3):240-5. Review.

PMID:
15977421
28.

Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma.

Sheehan KM, Calvert VS, Kay EW, Lu Y, Fishman D, Espina V, Aquino J, Speer R, Araujo R, Mills GB, Liotta LA, Petricoin EF 3rd, Wulfkuhle JD.

Mol Cell Proteomics. 2005 Apr;4(4):346-55. Epub 2005 Jan 25. Review.

29.

STUDENTJAMA. Molecular technologies for personalized cancer management.

Hasan RK, Wulfkuhle JD, Liotta LA, Petricoin EF.

JAMA. 2004 Apr 7;291(13):1644-5. No abstract available.

PMID:
15069056
30.

Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays.

Wulfkuhle JD, Aquino JA, Calvert VS, Fishman DA, Coukos G, Liotta LA, Petricoin EF 3rd.

Proteomics. 2003 Nov;3(11):2085-90.

PMID:
14595806
31.

Proteomic approaches to the diagnosis, treatment, and monitoring of cancer.

Wulfkuhle JD, Paweletz CP, Steeg PS, Petricoin EF 3rd, Liotta L.

Adv Exp Med Biol. 2003;532:59-68. Review.

PMID:
12908550
32.

Proteomic applications for the early detection of cancer.

Wulfkuhle JD, Liotta LA, Petricoin EF.

Nat Rev Cancer. 2003 Apr;3(4):267-75. Review.

PMID:
12671665
33.

Proteomics of human breast ductal carcinoma in situ.

Wulfkuhle JD, Sgroi DC, Krutzsch H, McLean K, McGarvey K, Knowlton M, Chen S, Shu H, Sahin A, Kurek R, Wallwiener D, Merino MJ, Petricoin EF 3rd, Zhao Y, Steeg PS.

Cancer Res. 2002 Nov 15;62(22):6740-9.

34.

New approaches to proteomic analysis of breast cancer.

Wulfkuhle JD, McLean KC, Paweletz CP, Sgroi DC, Trock BJ, Steeg PS, Petricoin EF 3rd.

Proteomics. 2001 Oct;1(10):1205-15. Review.

PMID:
11721633
35.

Domain analysis of supervillin, an F-actin bundling plasma membrane protein with functional nuclear localization signals.

Wulfkuhle JD, Donina IE, Stark NH, Pope RK, Pestonjamasp KN, Niswonger ML, Luna EJ.

J Cell Sci. 1999 Jul;112 ( Pt 13):2125-36.

36.

Cloning, characterization, and chromosomal localization of human superillin (SVIL).

Pope RK, Pestonjamasp KN, Smith KP, Wulfkuhle JD, Strassel CP, Lawrence JB, Luna EJ.

Genomics. 1998 Sep 15;52(3):342-51.

PMID:
9867483
37.
38.

Supervillin (p205): A novel membrane-associated, F-actin-binding protein in the villin/gelsolin superfamily.

Pestonjamasp KN, Pope RK, Wulfkuhle JD, Luna EJ.

J Cell Biol. 1997 Dec 1;139(5):1255-69.

39.

Vinculin binding site mapped on talin with an anti-idiotypic antibody.

Lee SW, Wulfkuhle JD, Otto JJ.

J Biol Chem. 1992 Aug 15;267(23):16355-8.

Supplemental Content

Loading ...
Support Center